Advertisement

International Journal of Clinical Pharmacy

, Volume 38, Issue 4, pp 985–995 | Cite as

Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals’ views

  • Yishen WangEmail author
  • Beata Bajorek
Research Article

Abstract

Background For stroke prevention in patients with atrial fibrillation (AF), the decision-making around antithrombotic therapy has been complicated by older age, multiple comorbidities, polypharmacy and the different pharmacological properties of warfarin and the nonvitamin K antagonist oral anticoagulants (NOACs). The complexity of decision-making has been associated with a reluctance by health professionals to use antithrombotic therapy, leading to poor clinical outcomes. In order to improve stroke prevention in patients with AF, the contemporary perspectives of health professionals on the decision-making around antithrombotic therapy needs exploration. Objective To elicit emerging themes describing health professionals’ perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Setting Sydney metropolitan area of New South Wales, Australia. Method A qualitative study based on face-to-face interviews was conducted from August to October 2014. Seven pharmacists, seven specialists, six general practitioners and six nurses practising in the Sydney metropolitan area and managing antithrombotic therapy for AF were interviewed until theme saturation was achieved in each subgroup. Interview transcripts were analysed using manual inductive coding. Main outcome measure Emerging themes describing health professionals’ perspectives on the decision-making around antithrombotic therapy for stroke prevention in patients with AF. Results Three overarching themes emerged. (1) Comprehensive assessment is necessary for decision-making but is not always implemented. Health professionals mostly focused on stroke risk assessment, not on the bleeding risk and medication safety issues. (2) Health professionals from different disciplines have different preferences for antithrombotic therapies. Although the majority of health professionals considered warfarin as the first-line therapy, NOACs were preferred by neurologists and haematologists. (3) Health professionals focused on different aspects of the decision making process: GPs and specialists were concerned about the appropriate prescription of antithrombotics, while pharmacists and nurses focused on daily medication management by patients. Conclusion The decision-making process appears to be partially preference based rather than systematic, and health professionals from various disciplines focus on different parts of the decision-making process.

Keywords

Atrial fibrillation Australia Decision making DOACs Health professionals Novel oral anticoagulant Stroke prevention Warfarin 

Notes

Acknowledgments

The authors would like to thank Ekta Pandya, Shamsher Singh, Riana Rahmawati, and Dr. Leigh Findlay for their assistance with this study.

Funding

No specific funding was used in the preparation of this manuscript.

Conflicts interest

None.

References

  1. 1.
    Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I. Balancing risk versus benefit: the elderly patient’s perspective on warfarin therapy. Pharm Pract (Internet). 2009;7(2):113–23.Google Scholar
  2. 2.
    Bajorek BV, Krass I, Ogle SJ, Duguid MJ, Shenfield GM. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. J Am Geriatr Soc. 2005;53(11):1912–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefPubMedGoogle Scholar
  4. 4.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Wang Y, Bajorek B. New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs. 2014;14(3):175–89.CrossRefPubMedGoogle Scholar
  6. 6.
    Janzic A, Kos M. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics. 2015;33(4):395–408.CrossRefPubMedGoogle Scholar
  7. 7.
    Bauer KA. Pros and cons of new oral anticoagulants. Am Soc Hematol Educ Program. 2013;2013:464–70.Google Scholar
  8. 8.
    Australian Government Department of Health and Ageing. Review of Anticoagulation Therapies in Atrial Fibrillation. 2012. http://www.pbs.gov.au/info/publication/factsheets/shared/anticoagulation-review. Accessed Oct 2013.
  9. 9.
    Australian Government Department of Health and Ageing. Review of Anticoagulation Therapies in Atrial Fibrillation. 2012. [Cited 2 Feb 2015] http://www.pbs.gov.au/reviews/atrial-fibrillation-files/1-flecknoe-brown.pdf;jsessionid=jsdcm8w02kwg69zg019sn9lq/.
  10. 10.
    Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257–354.CrossRefPubMedGoogle Scholar
  11. 11.
    You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e531S–75S.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Riva N, Smith DE, Lip GY, Lane DA. Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial fibrillation. Age Ageing. 2011;40(6):653–5.CrossRefPubMedGoogle Scholar
  13. 13.
    eTG complete [online]. Therapeutic guidelines: cardiovascular, version 6. Melbourne: Therapeutic Guidelines Limited. 2012.Google Scholar
  14. 14.
    Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17(10):1467–507.CrossRefPubMedGoogle Scholar
  15. 15.
    January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64(21):e1–e76.CrossRefPubMedGoogle Scholar
  16. 16.
    Bajorek B, Magin P, Hilmer S, Krass I. Contemporary approaches to managing atrial fibrillation: a survey of Australian general practitioners. Australas Med J. 2015;8(11):357–67.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16(3):308–19.CrossRefPubMedGoogle Scholar
  18. 18.
    Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation An update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385–413.CrossRefPubMedGoogle Scholar
  19. 19.
    Dantas GC, Thompson BV, Manson JA, Tracy CS, Upshur RE. Patients’ perspectives on taking warfarin: qualitative study in family practice. BMC Fam Pract. 2004;5(1):15.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
  21. 21.
    Bajorek BV, Masood N, Krass I. Development of a Computerised Antithrombotic Risk Assessment Tool (CARAT) to optimise therapy in older persons with atrial fibrillation. Australas J Ageing. 2012;31(2):102–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Patton M. Qualitative evaluation and research methods. Thousand Oaks, CA: Sage Publications Inc.; 2002.Google Scholar
  23. 23.
  24. 24.
    Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I, Bajorek BV, et al. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust. 2007;186(4):175–80.PubMedGoogle Scholar
  25. 25.
    Devereaux P, Anderson DR, Gardner MJ, Putnam W, Flowerdew GJ, Brownell BF, et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Commentary: varied preferences reflect the reality of clinical practice. BMJ. 2001;323(7323):1218.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Anderson N, Fuller R, Dudley N. ‘Rules of thumb’ or reflective practice? Understanding senior physicians’ decision-making about anti-thrombotic usage in atrial fibrillation. QJM. 2007;100(5):263–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Decker C, Garavalia L, Garavalia B, Simon T, Loeb M, Spertus JA, et al. Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc. 2012;5:129.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lip G, Zarifis J, Watson R, Beevers DG. Physician variation in the management of patients with atrial fibrillation. Heart. 1996;75(2):200–5.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Lip GY, Zarifis J, Watson RD, Beevers DG. Physician variation in the management of patients with atrial fibrillation. Heart. 1996;75(2):200–5.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Vassilikos VP, Mantziari A, Goudis CA, Paraskevaidis S, Dakos G, Giannakoulas G, et al. Differences in management of atrial fibrillation between cardiologists and non-cardiologists in Greece. Hell J Cardiol. 2010;51(2):113–21.Google Scholar
  31. 31.
    Lip GYH, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan G-A, et al. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. Europace. 2015;17(12):1777–86.CrossRefPubMedGoogle Scholar
  32. 32.
    Fuller R, Dudley N, Blacktop J. Avoidance hierarchies and preferences for anticoagulation: semi-qualitative analysis of older patients’ views about stroke prevention and the use of warfarin. Age Ageing. 2004;33(6):608–11.CrossRefPubMedGoogle Scholar
  33. 33.
    Wild D, Murray M, Donatti C. Patient perspectives on taking vitamin K antagonists: a qualitative study in the UK, USA and Spain. Expert Rev Pharmacoeconomics Outcomes Res. 2009;9(5):467–74.CrossRefGoogle Scholar
  34. 34.
    Lipman T, Murtagh MJ, Thomson R. How research-conscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study. Fam Pract. 2004;21(3):290–8.CrossRefPubMedGoogle Scholar
  35. 35.
    Wilke T, Groth A, Pfannkuche M, Harks O, Fuchs A, Maywald U, et al. Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. J Thromb Thrombolysis. 2015;40(1):97–107.CrossRefPubMedGoogle Scholar
  36. 36.
    De Breucker S, Herzog G, Pepersack T. Could geriatric characteristics explain the under-prescription of anticoagulation therapy for older patients admitted with atrial fibrillation? A retrospective observational study. Drugs Aging. 2010;27(10):807–13.CrossRefPubMedGoogle Scholar
  37. 37.
    Lipman T, Murtagh MJ, Thomson R. How research-conscious GPs make decisions about anticoagulation in patients with atrial fibrillation: a qualitative study. Fam Pract. 2004;21(3):290–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Australian Government Department of Human Services. Home Medicines Review (HMR). 2014. [Cited 01 July 2014] http://www.health.gov.au/internet/main/publishing.nsf/Content/medication_management_reviews.htm.

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  1. 1.Graduate School of Health-PharmacyThe University of Technology SydneySydneyAustralia
  2. 2.Department of PharmacyRoyal North Shore HospitalSydneyAustralia

Personalised recommendations